IDEAS home Printed from https://ideas.repec.org/f/psu347.html
   My authors  Follow this author

Moritz Suppliet

Personal Details

First Name:Moritz
Middle Name:
Last Name:Suppliet
Suffix:
RePEc Short-ID:psu347
https://sites.google.com/view/moritz-suppliet
Terminal Degree:2016 Düsseldorf Institute for Competition Economics (DICE); Wirtschaftswissenschaftliche Fakultät; Heinriche-Heine-Universität Düsseldorf (from RePEc Genealogy)

Affiliation

(80%) Tilburg Law and Economics Center (TILEC)
Universiteit van Tilburg

Tilburg, Netherlands
http://www.tilburguniversity.nl/tilec/
RePEc:edi:tilecnl (more details at EDIRC)

(20%) CentER Graduate School for Economics and Business
School of Economics and Management
Universiteit van Tilburg

Tilburg, Netherlands
https://www.tilburguniversity.edu/research/economics-and-management/graduate-school
RePEc:edi:cekubnl (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-033, Tilburg University, Center for Economic Research.
  2. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
  3. Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
  4. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
  5. Herr, A. & Suppliet, M., 2011. "Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 11/18, HEDG, c/o Department of Economics, University of York.

Articles

  1. Suppliet, Moritz, 2020. "Umbrella branding in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 73(C).
  2. Herr, Annika & Suppliet, Moritz, 2017. "Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals," Journal of Health Economics, Elsevier, vol. 56(C), pages 19-29.
  3. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
  4. Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics," Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1036-1057, September.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Suppliet, Moritz, 2020. "Umbrella branding in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 73(C).

    Mentioned in:

    1. Chris Sampson’s journal round-up for 5th October 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-10-05 11:00:05

Working papers

  1. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-033, Tilburg University, Center for Economic Research.

    Cited by:

    1. Laurent Cavenaile & Pau Roldan, 2019. "Advertising, innovation and economic growth," Working Papers 1902, Banco de España.
    2. Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2024. "Opium Price Shocks and Prescription Opioids in the USA," Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 86(3), pages 449-484, June.

  2. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.

    Cited by:

    1. Unsorg, Maximiliane, 2018. "Reference pricing systems on the pharmaceutical market," University of Tübingen Working Papers in Business and Economics 115, University of Tuebingen, Faculty of Economics and Social Sciences, School of Business and Economics.
    2. Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
    3. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-034, Tilburg University, Tilburg Law and Economic Center.
    4. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    5. Herr, Annika, 2012. "Rationalisierung und Wettbewerb im Arzneimittelmarkt," DICE Ordnungspolitische Perspektiven 31, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    6. Herr, Annika & Stühmeier, Torben & Wenzel, Tobias, 2014. "Reference pricing and cost-sharing: Theory and evidence on German off-patent drugs," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100556, Verein für Socialpolitik / German Economic Association.

  3. Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. Rebecca Cleary & Jean-Paul Chavas, 2022. "Strategic supermarket pricing of private labels and manufacturer brands," Empirical Economics, Springer, vol. 62(6), pages 2921-2950, June.
    3. Mats A. Bergman & David Granlund & Niklas Rudholm, 2016. "Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose," International Journal of Health Economics and Management, Springer, vol. 16(3), pages 201-214, September.
    4. Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
    5. Susan J. Méndez, 2018. "Parallel trade of pharmaceuticals: The Danish market for statins," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 333-356, February.
    6. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    7. Reisinger, Markus & Saurí, Lluís & Zenger, Hans, 2019. "Parallel imports, price controls, and innovation," Journal of Health Economics, Elsevier, vol. 66(C), pages 163-179.
    8. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-034, Tilburg University, Tilburg Law and Economic Center.
    9. Giorgio Gnecco & Berna Tuncay & Fabio Pammolli, 2018. "A Comparison of Game-Theoretic Models for Parallel Trade," International Game Theory Review (IGTR), World Scientific Publishing Co. Pte. Ltd., vol. 20(03), pages 1-57, September.
    10. Sarmah, Archita & De Giovanni, Domenico & De Giovanni, Pietro, 2020. "Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies," European Journal of Operational Research, Elsevier, vol. 282(3), pages 1053-1069.
    11. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
    12. Birg, Laura, 2022. "Pharmaceutical Regulation under Market Integration through Parallel Trade," VfS Annual Conference 2022 (Basel): Big Data in Economics 264128, Verein für Socialpolitik / German Economic Association.
    13. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 6430293b-fde9-4f91-ab35-3, Tilburg University, School of Economics and Management.
    14. Eduardo Costa & Carolina Santos, 2022. "Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1497-1518, December.
    15. Giorgio Gnecco & Fabio Pammolli & Berna Tuncay, 2022. "Welfare and research and development incentive effects of uniform and differential pricing schemes," Computational Management Science, Springer, vol. 19(2), pages 229-268, June.
    16. Bokhari, Farasat A.S. & Mariuzzo, Franco, 2018. "Demand estimation and merger simulations for drugs: Logits v. AIDS," International Journal of Industrial Organization, Elsevier, vol. 61(C), pages 653-685.
    17. Granlund David & Köksal-Ayhan Miyase Yesim, 2016. "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals: Has the Price Competition increased?," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 16(2), pages 1069-1092, April.
    18. David Granlund, 2022. "The Price Effects of Competition from Parallel Imports and Therapeutic Alternatives: Using Dynamic Models to Estimate the Causal Effect on the Extensive and Intensive Margins," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 60(1), pages 63-92, February.
    19. Farasat A.S. Bokhari & Franco Mariuzzo & Weijie Yan, 2019. "Antibacterial resistance and the cost of affecting demand: the case of UK antibiotics," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2019-03, Centre for Competition Policy, University of East Anglia, Norwich, UK..

  4. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).

    Cited by:

    1. Bauer, Cosima & May, Uwe, 2019. "Anpassung von AMNOG-Preisfaktoren im Zeitverlauf - Eine Analyse mit Fokus auf das Kriterium der europäischen Vergleichspreise: Gutachten für die Bristol-Myers Squibb GmbH & Co. KGaA," IBES Diskussionsbeiträge 225, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).

  5. Herr, A. & Suppliet, M., 2011. "Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 11/18, HEDG, c/o Department of Economics, University of York.

    Cited by:

    1. Unsorg, Maximiliane, 2018. "Reference pricing systems on the pharmaceutical market," University of Tübingen Working Papers in Business and Economics 115, University of Tuebingen, Faculty of Economics and Social Sciences, School of Business and Economics.
    2. Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
    3. Suppliet, Moritz, 2017. "Umbrella Branding in Pharmaceutical Markets," Discussion Paper 2017-034, Tilburg University, Tilburg Law and Economic Center.
    4. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    5. Herr, Annika, 2012. "Rationalisierung und Wettbewerb im Arzneimittelmarkt," DICE Ordnungspolitische Perspektiven 31, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    6. Herr, Annika & Stühmeier, Torben & Wenzel, Tobias, 2014. "Reference pricing and cost-sharing: Theory and evidence on German off-patent drugs," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100556, Verein für Socialpolitik / German Economic Association.

Articles

  1. Suppliet, Moritz, 2020. "Umbrella branding in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 73(C).
    See citations under working paper version above.
  2. Herr, Annika & Suppliet, Moritz, 2017. "Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals," Journal of Health Economics, Elsevier, vol. 56(C), pages 19-29.

    Cited by:

    1. Annika Herr & Torben Stühmeier & Tobias Wenzel, 2023. "More cost‐sharing, less cost? Evidence on reference price drugs," Health Economics, John Wiley & Sons, Ltd., vol. 32(2), pages 413-435, February.
    2. Eduardo Costa & Carolina Santos, 2022. "Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1497-1518, December.
    3. Ya-Ling Lin & Wen-Yi Chen & Shwn-Huey Shieh, 2020. "Age Structural Transitions and Copayment Policy Effectiveness: Evidence from Taiwan’s National Health Insurance System," IJERPH, MDPI, vol. 17(12), pages 1-17, June.

  3. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    See citations under working paper version above.
  4. Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics," Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1036-1057, September.
    See citations under working paper version above.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 10 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-COM: Industrial Competition (9) 2012-05-02 2014-04-11 2014-04-18 2014-12-24 2015-02-16 2016-10-23 2016-11-20 2017-10-08 2018-01-01. Author is listed
  2. NEP-HEA: Health Economics (5) 2012-05-02 2016-10-23 2016-11-20 2017-10-08 2018-01-01. Author is listed
  3. NEP-MKT: Marketing (4) 2016-10-23 2016-11-20 2017-10-08 2018-01-01
  4. NEP-EUR: Microeconomic European Issues (3) 2014-04-11 2014-04-18 2014-12-24
  5. NEP-IPR: Intellectual Property Rights (3) 2012-05-02 2017-10-08 2018-01-01
  6. NEP-GER: German Papers (2) 2014-04-11 2014-05-24
  7. NEP-IAS: Insurance Economics (2) 2016-10-23 2016-11-20
  8. NEP-IND: Industrial Organization (2) 2016-11-20 2017-10-08
  9. NEP-HME: Heterodox Microeconomics (1) 2012-05-02
  10. NEP-REG: Regulation (1) 2016-10-23

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Moritz Suppliet should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.